Bharat Biotech said on Tuesday that its vaccine candidate -Covaxin - can offer protection against mutations of coronavirus. Bharat Biotech Chairman and Managing Director Krishna Ella said the protein components of inactive Covaxin will take care of mutations. Hyderabad-based Bharat Biotech is developing Covaxin in collaboration with the Indian Council of Medical Research (ICMR). The phase 3 efficacy trials of Covaxin are in progress with 20,000 volunteers, Ella said. Serum Institute-Oxford's Covishield, Bharat Biotech's Covaxin and Pfizer vaccine are in the fray for emergency use authorisation.

Source: dna December 30, 2020 02:15 UTC